

NO. 91472-R7

LUNG VOLUME REDUCTION (SURGICAL AND NON-SURGICAL)

Effective date: 03/01/2026**Last reviewed:** 02/2026

Instructions for use: This document is for informational purposes only. Coverage is subject to member's specific benefits. Group specific policy will supersede this policy when applicable. Eligibility and benefit coverage are determined in accordance with the terms of the member's plan in effect as of the date services are rendered. It is not an authorization, certification, explanation of benefits, or contract. Receipt of benefits is subject to satisfaction of all terms and conditions of coverage. Priority Health's medical policies are developed with the assistance of medical professionals and are based upon a review of published and unpublished information including, but not limited to, current medical literature, guidelines published by public health and health research agencies, and community medical practices in the treatment and diagnosis of disease. Because medical practice, information, and technology are constantly changing, Priority Health reserves the right to review and update its medical policies at its discretion. Priority Health's medical policies are intended to serve as a resource to the plan. They are not intended to limit the plan's ability to interpret plan language as deemed appropriate. Physicians and other providers are solely responsible for all aspects of medical care and treatment, including the type, quality, and levels of care and treatment they choose to provide.

Policy scope: This medical policy outlines the coverage parameters, medical necessity criteria, and applicable regulatory and guideline frameworks for lung volume reduction interventions, including both surgical lung volume reduction surgery (LVRS) and bronchoscopic (non-surgical) lung volume reduction (BLVR)

Related policies: None

I. MEDICAL NECESSITY CRITERIA

A. **Lung Volume Reduction Surgery (LVRS):** Priority Health considers LVRS medically necessary when all of the following are present:

1. Either of the following:
 - a. Severe upper lobe emphysema; or
 - b. Severe non-upper lobe emphysema with low exercise capacity.
2. Pulmonary Rehabilitation as follows:
 - a. Pre-operative: 6 - 10 week series of at least 16, and no more than 20, preoperative sessions each lasting a minimum of two hours.
 - b. Post-operative: at least 6 and no more than 10 postoperative sessions each lasting a minimum of two hours, within 8 to 9 weeks of the LVRS.

- c. Specific components of the pulmonary rehabilitation program must include:
- Comprehensive evaluation of medical, psychosocial and nutritional needs
 - Setting of goals for education and exercise training
 - Exercise training (lower extremity, flexibility, strengthening, and upper extremity)
 - Education about emphysema and medical treatments
 - Psychosocial counseling
 - Nutritional counseling

3. ALL of the following:

- a. Radiographic evidence of moderate to severe bilateral emphysema,
- b. Forced expiratory volume in one second (FEV 1) < 45% predicted or > 15% predicted if age > 70 years)
- c. Non-smoking for at least 4 months
- d. Participation in pulmonary rehabilitation with the attainment of preset performance goals (e.g., ability to complete three minute unloaded pedaling in an exercise tolerance test).

4. NONE of the following:

- a. Previous LVRS or lobectomy,
- b. Patient is high risk. High-risk patient is defined as one with a forced expiratory volume in the first second (FEV1) that is 20% or less of their predicted value and either homogeneous distribution of emphysema on CT scan or low carbon monoxide diffusing capacity (DLCO) that is 20% or less of their predicted value.
- c. COPD conditions unsuitable for LVRS (e.g., bronchiectasis, chronic bronchitis, and CT evidence of diffuse emphysema judged unsuitable),
- d. Systemic disease or neoplasias expected to compromise survival during five-year period,
- e. Medical conditions or other circumstances make it likely that the patient will be unable to complete the pre- and postoperative pulmonary diagnostic and therapeutic program required for surgery

5. LVRS approach must be a bilateral excision of damaged lung with stapling performed via median sternotomy or video-assisted thoracoscopic surgery.

B. Bronchoscopic (non-surgical) lung volume reduction (BLVR) for Chronic Obstructive Lung Disease:

Priority Health considers the implantation of FDA approved endobronchial valves (e.g., Zephyr® Endobronchial Valves (Pulmonx), Spiration (Olympus Respiratory, etc.), medically necessary only for the indication of emphysema, and only if the patient meets **ALL** of the listed selection criteria and exhibits **NONE** of the listed contraindications.

1. **Patient Selection Criteria** (patient must meet ALL):

- a. Diagnosis of emphysema confirmed by CT
- b. Body Mass Index (BMI) < 35 kg/m²
- c. Stable with ≤ 20 mg prednisone (or equivalent) daily
- d. Residual Volume (RV) ≥ 175% predicted (≥ 200% if homogeneous)
- e. Force Expiratory Volume in 1 second (FEV1) between 15 and 45% predicted
- f. Total Lung Capacity (TLC) ≥ 100% predicted
- g. Diffusing Capacity for carbon monoxide (DLCO) ≥ 20% predicted
- h. 6-minute walk distance (6MWD) 100-500 m (150-500 m if homogeneous)
- i. Not actively smoking (smoking cessation for at least 4 months leading up to procedure)
- j. Completed and submitted preliminary assessment of collateral ventilation within target lobe (as measured by Chartis® Assessment and/or StratX® Lung Analysis Platform; or SeleCT™ QCT analysis service)

2. **Contraindications** (patient must exhibit **NONE**):

- a. Bronchoscopic procedures are contraindicated
- b. Evidence of active pulmonary infection
- c. Known allergies to Nitinol, Nickel, Titanium, or Silicone
- d. Current smoker
- e. Large bullae encompassing greater than 30% of either lung
- f. Less than 85% fissure integrity in the lobe intended to be treated as measured by quantitative CT fissure analysis or Chartis® Assessment.

C. **Exclusions:** Priority Health considers any of the following experimental, investigational, and/or unproven, and therefore not medically necessary, as there is insufficient published evidence to assess the safety and/or impact on health outcomes or patient management:

1. Endobronchial **coils** (including, but not limited to, the following: PneumRx (PneumRx Inc.))

II. **CENTERS FOR MEDICARE & MEDICAID SERVICES (CMS) COVERAGE DETERMINATION**

Any applicable federal or state mandates will take precedence over this medical coverage policy.

Medicare: Refer to the [CMS Online Manual System \(IOMs\)](#) and Transmittals.

For the most current applicable CMS National Coverage Determination (NCD)/Local Coverage Determination (LCD)/Local Coverage Article (LCA) refer to [CMS Medicare Coverage Database](#).

The information below is current as of the review date for this policy. However, the coverage issues and policies maintained by CMS are updated and/or revised periodically. Therefore, the most current CMS information may not be contained in this document. MAC jurisdiction for purposes of local coverage determinations is governed by the geographic service area where the Medicare Advantage plan is contracted to provide the service. Please refer to the Medicare [Coverage Database website](#) for the most current applicable NCD, LCD, LCA, and CMS Online Manual System/Transmittals.

National Coverage Determinations (NCDs)	
Lung Volume Reduction Surgery (Reduction Pneumoplasty) 240.1	
Local Coverage Determinations (LCDs)	
CGS Administrators, LLC	None identified
First Coast Service Options, Inc.	None identified
National Government Services, Inc.	None identified
Noridian Healthcare Solutions	None identified
Novitas Solutions, Inc.	None identified
Palmetto GBA	None identified
WPS Insurance Corporation	None identified

III. BACKGROUND

Lung volume reduction surgery (LVRS) involves removal of bullae and nonfunctional lung tissue in patients with **chronic obstructive pulmonary disease (COPD)** due to emphysema. The objective of this procedure is to allow re-expansion of the remaining compressed lung, which in turn may allow the lung to inflate to a more normal capacity and to function more efficiently, and may reduce the size of the thoracic cavity to achieve a more optimal respiratory muscle action and ventilatory capacity.

There is some evidence from randomized trials that LVRS can produce significant improvements in pulmonary function, dyspnea, exercise capacity, and quality of life compared with medical therapy in selected patients with upper lobe pathology, and can reduce mortality in patients with upper lobe pathology and low exercise tolerance. However, LVRS can also increase mortality in certain patient populations, and there is a relatively high early mortality rate associated with the procedure. LVRS is palliative not curative.

Bronchoscopic lung volume reduction (BLVR) entails nonsurgical physical intervention with access from the nose or mouth to the lungs, targeting diseased tissue identified by imaging. Valves provide one-way flow that allow air to exit but not enter segments distal to where they are implanted, reducing air trapping. When valves are in place, expiration of air continues normally but air flow on inspiration is blocked, which is intended to cause the upper lobes to gradually lose volume and collapse.

Endobronchial valves are implantable bronchial valves indicated for the bronchoscopic treatment of adult patients with hyperinflation associated with severe emphysema in regions of the lung that have little to no collateral ventilation (airflow between lobes through channels that bypass normal airways).

The **Chartis® System** is a proprietary pulmonary assessment tool that enables physicians to identify those patients likely to respond to the Pulmonx Zephyr valves with a high degree of confidence. The Chartis system provides precise flow and pressure readings for specific lobes in the lungs to assess collateral ventilation. Clinical studies outside of the US have shown that patients with low to no collateral ventilation respond best to Zephyr valve therapy.

StratX® is a cloud-based quantitative CT analysis service that supports Zephyr valve patient selection and treatment targeting by providing clinically validated information on emphysema destruction, fissure completeness and volume.

Olympus offers the **SeleCT™ QCT** analysis service to evaluate patient eligibility for treatment with the Spiration® Valve System. The SeleCT QCT analysis service analyzes previously taken CT images to quantify important measures of emphysema, including emphysema distribution (heterogeneity), the severity of lung tissue destruction and fissure integrity between the lobes of the lung (which has been shown to be a surrogate for collateral ventilation).

Clinical Practice Guidelines and Position Statements

National Institute of Health and Care Excellence (NICE). Endobronchial Valve Insertion to Reduce Lung Volume in Emphysema (2017):

"Current evidence on the safety and efficacy of [EBV] insertion to reduce lung volume in emphysema is adequate in quantity and quality to support the use of this procedure provided that standard arrangements are in place for clinical governance, consent and audit" (p. 2).

Lung Foundation of Australia. The COPD-X Plan: Australian and New Zealand Guidelines for the Management of Chronic Obstructive Pulmonary Disease (2024):

"[EBVs] may be appropriate in highly selected patients with severe COPD and hyperinflation if collateral ventilation can be excluded (intact fissure on imaging and Chartis negative during bronchoscopy)" (p. 92).

Canadian Agency for Drugs and Technology in Health. Endobronchial Valves for the Management of Severe Emphysema (2024):

"[EBVs] are a potential therapy for people with severe emphysema with some favourable clinical and cost outcomes, but the evidence for their safety is unclear" (p. 3).

Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of COPD (2025):

"In selected patients with heterogeneous or homogenous emphysema and significant hyperinflation refractory to optimized medical care, surgical or bronchoscopic modes of lung volume reduction (e.g., [one-way EBV], lung coils, or thermal ablation) may be considered" (p. 103).

IV. GUIDELINES / POSITION STATEMENTS

Medical/Professional Society	Guideline
Global Initiative For Chronic Obstructive Lung Disease	Global Strategy for the Diagnosis, Management, and Prevention of COPD (2025)
Canadian Agency for Drugs and Technologies in Health	CADTH Health Technology Review: Endobronchial Valves for the Management of Severe Emphysema (January 2024)
Lung Foundation Australia	The COPD-X Plan:

	Australian and New Zealand Guidelines for the Management of Chronic Obstructive Pulmonary Disease (2024)
National Institute of Health and Care Excellence (NICE)	Endobronchial valve insertion to reduce lung volume in emphysema. Interventional procedures guidance. Reference number:IPG600 (December 20, 2017)

V. REGULATORY (US FOOD AND DRUG ADMINISTRATION)

See [U.S. Food & Drug Administration \(FDA\) Medical Device Databases](#) for the most current information.

Device	Premarket Approval, 513(f)(2)(De Novo), or 510(k) Number	Notice date
Spiration® Valve System (Gyrus Acmi, Inc.)	P180007	December 3, 2018
Zephyr Endobronchial Valve System (Pulmonx Corp.)	P180002	June 29, 2018
Chartis Precision Catheter (Pulmonx Corp.)	K222340	December 1, 2022
Pulmonx Chartis Tablet Console (Pulmonx Corp.)	K180011	July 13, 2018
Chartis Console (Pulmonx, Inc.)	K111764	November 10, 2011
Chartis Catheter Model CHR-CA-12.0 (Pulmonx, Inc.)	K111522	September 29, 2011
Chartis Catheter (Pulmonx, Inc.)	K083883	June 25, 2009
Chartis Console (Pulmonx, Inc.)	K083199	June 25, 2009

VI. CODING

ICD-10 Codes that may support medical necessity

J43.0 - J43.9 Emphysema

CPT/HCPCS Codes

- 31647 Bronchoscopy, rigid or flexible, including fluoroscopic guidance, when performed; with balloon occlusion, when performed, assessment of air leak, airway sizing, and insertion of bronchial valve(s), initial lobe
- 31648 Bronchoscopy, rigid or flexible, including fluoroscopic guidance, when performed; with removal of bronchial valve(s), initial lobe
- 31649 Bronchoscopy, rigid or flexible, including fluoroscopic guidance, when performed; with removal of bronchial valve(s), each additional lobe (List separately in addition to code for primary procedure)
- 31651 Bronchoscopy, rigid or flexible, including fluoroscopic guidance, when performed; with balloon occlusion, when performed, assessment of air leak, airway sizing,

and insertion of bronchial valve(s), each additional lobe (List separately in addition to code for primary procedure[s])

32141 Thoracotomy; with resection-plication of bullae, includes any pleural procedure when performed

32491 Removal of lung, other than total pneumonectomy; excision-plication of emphysematous lung(s) (bullous or non-bullous) for lung volume reduction, sternal split or transthoracic approach, with or without any pleural procedure

32655 Thoracoscopy, surgical; with resection-plication of bullae, includes any pleural procedure when performed

32672 Thoracoscopy, surgical; with resection-plication for emphysematous lung (bullous or non-bullous) for lung volume reduction (LVRS), unilateral includes any pleural procedure, when performed

Billed by facilities under only:

G0302 Preoperative pulmonary surgery services for preparation for LVRS, complete course of services, to include a minimum of 16 days of services

G0303 Preoperative pulmonary surgery services for preparation for LVRS, 10 to 15 days of services

G0304 Preoperative pulmonary surgery services for preparation for LVRS, 1 to 9 days of services

G0305 Post discharge pulmonary surgery services after LVRS, minimum of 6 days of services

VII. MEDICAL NECESSITY REVIEW

Prior authorization for certain drugs, devices, services and procedures may or may not be required. In cases where prior authorization is required, providers will submit a request demonstrating that a drug, service or procedure is medically necessary. For more information, refer to the [Priority Health Provider Manual](#).

Individual case review may allow coverage for care or treatment that is investigational yet promising for the conditions described. Requests for individual consideration require prior plan approval. All determinations of coverage for experimental, investigational, or unproven treatment will be made by a Priority Health medical director or clinical pharmacist. The exclusion of coverage for experimental, investigational, or unproven treatment may be reviewed for exception if the condition is either a terminal illness, or a chronic, life threatening, severely disabling disease that is causing serious clinical deterioration.

VIII. APPLICATION TO PRODUCTS

Coverage is subject to the member's specific benefits. Group-specific policy will supersede this policy when applicable.

- **HMO/EPO:** This policy applies to insured HMO/EPO plans.
- **POS:** This policy applies to insured POS plans.

- **PPO:** This policy applies to insured PPO plans. Consult individual plan documents as state mandated benefits may apply. If there is a conflict between this policy and a plan document, the provisions of the plan document will govern.
- **ASO:** For self-funded plans, consult individual plan documents. If there is a conflict between this policy and a self-funded plan document, the provisions of the plan document will govern.
- **INDIVIDUAL:** For individual policies, consult the individual insurance policy. If there is a conflict between this medical policy and the individual insurance policy document, the provisions of the individual insurance policy will govern.
- **MEDICARE:** Coverage is determined by the Centers for Medicare and Medicaid Services (CMS); if a coverage determination has not been adopted by CMS, this policy applies.
- **MEDICAID/HEALTHY MICHIGAN PLAN:** For Medicaid/Healthy Michigan Plan members, this policy will apply. Coverage is based on medical necessity criteria being met and the appropriate code(s) from the coding section of this policy being included on the [Michigan Medicaid Fee Schedule](#). If there is a discrepancy between this policy and the [Michigan Medicaid Provider Manual](#), the Michigan Medicaid Provider Manual will govern. If there is a discrepancy or lack of guidance in the Michigan Medicaid Provider Manual, the Priority Health contract with Michigan Medicaid will govern. For Medical Supplies/DME/Prosthetics and Orthotics, please refer to the Michigan Medicaid Fee Schedule to verify coverage.

IX. REFERENCES

Guidelines/Position Statements

1. Canadian Agency for Drugs and Technology in Health. Endobronchial Valves for the Management of Severe Emphysema. 2024.
2. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of COPD. 2025.
3. National Institute for Health and Care Excellence (NICE). Endobronchial valve insertion to reduce lung volume in emphysema. Interventional procedures guidance [IPG600]. 2017.
4. Yang IA, George J, McDonald CF, Disler R, Ordman R, Goodwin A, Smith B, McNamara R, Zwar N, Dabscheck E. The COPD-X Plan: Australian and New Zealand Guidelines for the management of Chronic Obstructive Pulmonary Disease 2024. Version 2.77, December 2024. Published online 09 April 2025
<https://copdx.org.au/copd-x-plan/>

Additional References

5. Criner GJ, Sue R, Wright S, Dransfield M, Rivas-Perez H, Wiese T, Scieurba FC, Shah PL, Wahidi MM, de Oliveira HG, Morrissey B, Cardoso PFG, Hays S, Majid A, Pastis N Jr, Kopas L, Vollenweider M, McFadden PM, Machuzak M, Hsia DW, Sung A, Jarad N, Kornaszewska M, Hazelrigg S, Krishna G, Armstrong B, Shargill NS, Slebos DJ; LIBERATE Study Group. A Multicenter Randomized Controlled Trial of Zephyr Endobronchial Valve Treatment in Heterogeneous Emphysema (LIBERATE). *Am J Respir Crit Care Med*. 2018 Nov 1;198(9):1151-1164. doi: 10.1164/rccm.201803-0590OC. PMID: 29787288.
6. Gompelmann D, Heinhold T, Rötting M, Bischoff E, Kontogianni K, Eberhardt R, Herth FJF. Long-term follow up after endoscopic valve therapy in patients with

- severe emphysema. *Ther Adv Respir Dis*. 2019 Jan-Dec;13:1753466619866101. doi: 10.1177/1753466619866101. PMID: 31373259; PMCID: PMC6681249.
7. Hayes, Inc. Clinical Research Response. Zephyr Endobronchial Valve (Pulmonx Corp.). Hayes, Inc. May 14, 2025.
 8. Hayes, Inc. Health Technology Assessment. Comparative Effectiveness Review of Bronchoscopically Placed Coils or Valves for Lung Emphysema: A Review of Reviews. Hayes, Inc. February 25, 2019. Annual Review January 18, 2022.
 9. Hayes, Inc. Health Technology Assessment. Lung Volume Reduction Surgery for Chronic Obstructive Pulmonary Disease. Hayes, Inc. December 9, 2003. Annual Review January 11, 2008.
 10. Kemp SV, Slebos DJ, Kirk A, Kornaszewska M, Carron K, Ek L, Broman G, Hillerdal G, Mal H, Pison C, Briault A, Downer N, Darwiche K, Rao J, Hübner RH, Ruwwe-Glosenkamp C, Trosini-Desert V, Eberhardt R, Herth FJ, Derom E, Malfait T, Shah PL, Garner JL, Ten Hacken NH, Fallouh H, Leroy S, Marquette CH; TRANSFORM Study Team *. A Multicenter Randomized Controlled Trial of Zephyr Endobronchial Valve Treatment in Heterogeneous Emphysema (TRANSFORM). *Am J Respir Crit Care Med*. 2017 Dec 15;196(12):1535-1543. doi: 10.1164/rccm.201707-1327OC. PMID: 28885054.
 11. Li S, Wang G, Wang C, Gao X, Jin F, Yang H, Han B, Zhou R, Chen C, Chen L, Bai C, Shen H, Herth FJF, Zhong N. The REACH Trial: A Randomized Controlled Trial Assessing the Safety and Effectiveness of the Spiration® Valve System in the Treatment of Severe Emphysema. *Respiration*. 2019;97(5):416-427. doi: 10.1159/000494327. Epub 2018 Dec 14. PMID: 30554211; PMCID: PMC6549456.
 12. Ramsey SD, Berry K, Etzioni R, Kaplan RM, Sullivan SD, Wood DE; National Emphysema Treatment Trial Research Group. Cost effectiveness of lung-volume-reduction surgery for patients with severe emphysema. *N Engl J Med*. 2003 May 22;348(21):2092-102. doi: 10.1056/NEJMsa030448. Epub 2003 May 20. PMID: 12759480.

Past review dates: 11/2003, 11/2004, 10/2005, 10/2006, 10/2007, 10/2008, 10/2009, 10/2010, 10/2011, 10/2012, 10/2013, 11/2014, 11/2015, 11/2016, 11/2017, 11/2018, 05/2019, 05/2020, 05/2021, 02/2022, 02/2023, 02/2024, 02/2025, 02/2026

AMA CPT Copyright Statement: All Current Procedure Terminology (CPT) codes, descriptions, and other data are copyrighted by the American Medical Association.

The name "Priority Health" and the term "plan" mean Priority Health, Priority Health Managed Benefits, Inc., Priority Health Insurance Company and Priority Health Government Programs, Inc.